AKT1 and lung carcinoma: When lung cancer cell A549 and H1975 were treated with PI3K-kinase inhibitor LY294002 for 48 h, the results demonstrated that LY294002 increased the expression of PTEN and decreased the STMN1 and p-AKT protein levels (Fig. 4c).